There are 749 resources available
Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion
Presenter: John Chia
Session: AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine
Resources:
Slides
Webcast
Closing
Presenter: Byoung-Gie Kim
Session: AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine
Resources:
Slides
Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC
Presenter: Marina Garassino
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
EGFR mutant mNSCLC: Single agent or in combination?
Presenter: Fabrice Barlesi
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
Future development for the use of biomarkers
Presenter: Ross Soo
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
PARPi maintenance: A new paradigm in the management of frontline ovarian cancer
Presenter: Shaheenah Dawood
Session: AstraZeneca - PARP inhibitors as targeted therapy for personalised medicine
Resources:
Slides
Webcast
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Presenter: Myung-Ju Ahn
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
Presenter: Yi-Long Wu
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
High incidence and mortality of transitional cell carcinoma in Thai kidney transplant patients
Presenter: Suthanit Laowalert
Session: Mini Oral session - Genitourinary tumours
Resources:
Slides
Webcast
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Presenter: Thanyanan Reungwetwattana
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast